Pathogenesis of hepatic steatosis: The link between hypercortisolism and non-alcoholic fatty liver disease
Authors:
- Giovanni TarantinoGiovanni Tarantino
- Carmine FinelliCFCarmine Finelli
Open Access
- 1 January 2013
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (40) , 6735-43
Abstract
Based on the available literature, non alcoholic fatty liver disease or generally speaking, hepatic steatosis, is more frequent among people with diabetes and obesity, and is almost universally present amongst morbidly obese diabetic patients. Non alcoholic fatty liver disease is being increasingly recognized as a common liver condition in the developed world, with non alcoholic steatohepatitis projected to be the leading cause of liver transplantation. Previous data report that only 20% of patients with Cushing's syndrome have hepatic steatosis. Aiming at clarifying the reasons whereby patients suffering from Cushing's syndrome - a condition characterized by profound metabolic changes - present low prevalence of hepatic steatosis, the Authors reviewed the current concepts on the link between hypercortisolism and obesity/metabolic syndrome. They hypothesize that this low prevalence of fat accumulation in the liver of patients with Cushing's syndrome could result from the inhibition of the so-called low-grade chronic-inflammation, mainly mediated by Interleukin 6, due to an excess of cortisol, a hormone characterized by an anti-inflammatory effect. The Cushing's syndrome, speculatively considered as an in vivo model of the hepatic steatosis, could also help clarify the mechanisms of non alcoholic fatty liver disease.Keywords
This publication has 94 references indexed in Scilit:
- 11β-Hydroxysteroid Dehydrogenase Type 1, But Not Type 2, Deficiency Worsens Acute Inflammation and Experimental Arthritis in MiceEndocrinology, 2012
- Diagnosis and Evaluation of Nonalcoholic Fatty Liver DiseaseExperimental Diabetes Research, 2011
- 11β-Hydroxysteroid Dehydrogenase-1 Is a Novel Regulator of Skin Homeostasis and a Candidate Target for Promoting Tissue RepairPLOS ONE, 2011
- Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese femalesJournal of Translational Medicine, 2011
- 11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progressFrontiers in Neuroendocrinology, 2011
- Adamantyl Ethanone Pyridyl Derivatives: Potent and Selective Inhibitors of Human 11β‐Hydroxysteroid Dehydrogenase Type 1ChemMedChem, 2011
- Cortisone-reductase deficiency associated with heterozygous mutations in 11β-hydroxysteroid dehydrogenase type 1Proceedings of the National Academy of Sciences, 2011
- The ubiquitous interleukin-6: a time for reappraisalCardiovascular Diabetology, 2010
- Specificity of Screening Tests for Cushing’s Syndrome in an Overweight and Obese PopulationThe Journal of Clinical Endocrinology & Metabolism, 2009
- Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively?Journal of Inflammation, 2009